Voyager Q1 Revenue $2.59M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy VYGR?
Reports Q1 revenue $2.59M, consensus $8.79M. "As the 'Year of Tau' for Alzheimer's disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to confirm tau knockdown as the next critical approach to treating Alzheimer's disease. Then, in the second half of the year, we expect first-in-human dosing of our tau silencing gene therapy VY1706 and tau PET imaging efficacy data for our anti-tau antibody VY7523," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "With our strong cash position of $172 million that is expected to provide runway into 2028, we continue to execute across our pipeline and platforms."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VYGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VYGR
Wall Street analysts forecast VYGR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.960
Low
8.00
Averages
13.20
High
25.00
Current: 3.960
Low
8.00
Averages
13.20
High
25.00
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Voyager Therapeutics Q1 Financial Results Analysis
- Revenue and Loss: In Q1 2026, Voyager Therapeutics reported revenue of $2.6 million and a net loss of $27.9 million, indicating significant challenges in profitability despite a slight increase in revenue.
- R&D Expense Reduction: R&D expenses for Q1 were $24.6 million, down from $31.5 million in Q1 2025, primarily due to cost-cutting and efficiency initiatives, although increased costs related to the tau silencing gene therapy program suggest strategic shifts in R&D focus.
- Decrease in Administrative Costs: General and administrative expenses decreased to $8.3 million in Q1 2026 from $9.6 million in the previous year, reflecting effective cost control measures taken by the company to address ongoing financial pressures.
- Cash Flow Position: As of March 31, 2026, Voyager had $171.7 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet operating and capital expenditure needs through 2028, indicating a degree of financial stability.
See More
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
- Orphan Drug Status: The FDA has granted orphan drug designation to Neurocrine Biosciences' NBIB-223 (frataxin), which allows for up to seven years of market exclusivity post-approval, significantly enhancing its commercial potential.
- Tax Incentives: With orphan drug status, NBIB-223 will benefit from tax credits for clinical trial expenses, reducing R&D costs and thereby strengthening Neurocrine's competitive position in the Friedreich ataxia treatment landscape.
- Gene Therapy Innovation: NBIB-223 is a gene therapy that employs Voyager Therapeutics' modified AAV capsid to deliver the frataxin gene throughout the body, showcasing Neurocrine's commitment to cutting-edge medical technology and innovation.
- Market Competition: The only approved treatment for Friedreich ataxia is Biogen's Skyclarys (omaveloxolone), and the introduction of NBIB-223 will provide patients with more options while potentially challenging Biogen's market share.
See More
VY1706 Gene Therapy Shows Safety in Alzheimer's Study
- Preclinical Data Showcase: VY1706 demonstrates compelling pharmacology and safety in a three-month GLP toxicology study in non-human primates, indicating its potential as a treatment for Alzheimer's disease, with clinical trials expected to commence in the second half of 2026, potentially offering new therapeutic options for patients.
- Technological Innovation: The novel AAV capsids developed through Voyager's TRACER platform effectively penetrate the blood-brain barrier and achieve widespread drug expression, enhancing treatment capabilities for Alzheimer's while opening new avenues for other neurological disorders.
- Immune Evasion Strategy: The application of new technologies allows VY1706 to expand the eligible patient population while minimizing immune responses, which not only improves treatment efficacy but also potentially reduces side effects, increasing patient acceptance.
- Future Development Plans: Voyager aims to submit an IND application in Q2 2026, marking a significant advancement in its Alzheimer's program, which is expected to create new market opportunities and bolster investor confidence.
See More
Voyager Therapeutics CFO Resignation and New Appointment
- Executive Changes: Voyager Therapeutics CFO Nathan Jorgensen announced his resignation effective May 8, 2026, to pursue a new opportunity, leading to potential instability in financial leadership that may affect investor confidence.
- New Financial Leadership: The Board has appointed current COO and CBO Robin Swartz as the new Principal Financial Officer and Treasurer effective immediately, ensuring continuity in financial leadership aimed at stabilizing company operations.
- Enhanced Accounting Oversight: Amy Quinlan has been named Principal Accounting Officer, strengthening the company's accounting oversight, indicating a commitment to financial transparency and compliance.
- Stock Price Reaction: Following the executive changes announcement, Voyager Therapeutics' stock closed approximately 2.60% lower at around $4.12, reflecting market caution regarding the leadership transition.
See More
Voyager Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Voyager Therapeutics reported a Q4 GAAP EPS of -$0.46, beating expectations by $0.07, indicating an improving trend in the company's profitability metrics.
- Collaboration Revenue Surge: The company achieved collaboration revenue of $15.34 million, representing a 144.3% year-over-year increase, which not only exceeded market expectations by $4.85 million but also reflects the success of its strategic partnerships and strong market demand.
- Cash Position: As of December 31, 2025, Voyager's cash, cash equivalents, and marketable securities totaled $201.7 million, ensuring sufficient funding for future R&D and operational activities.
- Market Outlook: With significant growth in collaboration revenue and a robust cash position, Voyager Therapeutics is poised to enhance its competitive edge in the biopharmaceutical sector, supporting the realization of its long-term strategic objectives.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
Voyager Therapeutics Q1 Financial Results Analysis
- Revenue and Loss: In Q1 2026, Voyager Therapeutics reported revenue of $2.6 million and a net loss of $27.9 million, indicating significant challenges in profitability despite a slight increase in revenue.
- R&D Expense Reduction: R&D expenses for Q1 were $24.6 million, down from $31.5 million in Q1 2025, primarily due to cost-cutting and efficiency initiatives, although increased costs related to the tau silencing gene therapy program suggest strategic shifts in R&D focus.
- Decrease in Administrative Costs: General and administrative expenses decreased to $8.3 million in Q1 2026 from $9.6 million in the previous year, reflecting effective cost control measures taken by the company to address ongoing financial pressures.
- Cash Flow Position: As of March 31, 2026, Voyager had $171.7 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet operating and capital expenditure needs through 2028, indicating a degree of financial stability.
See More
FDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
- Orphan Drug Status: The FDA has granted orphan drug designation to Neurocrine Biosciences' NBIB-223 (frataxin), which allows for up to seven years of market exclusivity post-approval, significantly enhancing its commercial potential.
- Tax Incentives: With orphan drug status, NBIB-223 will benefit from tax credits for clinical trial expenses, reducing R&D costs and thereby strengthening Neurocrine's competitive position in the Friedreich ataxia treatment landscape.
- Gene Therapy Innovation: NBIB-223 is a gene therapy that employs Voyager Therapeutics' modified AAV capsid to deliver the frataxin gene throughout the body, showcasing Neurocrine's commitment to cutting-edge medical technology and innovation.
- Market Competition: The only approved treatment for Friedreich ataxia is Biogen's Skyclarys (omaveloxolone), and the introduction of NBIB-223 will provide patients with more options while potentially challenging Biogen's market share.
See More
VY1706 Gene Therapy Shows Safety in Alzheimer's Study
- Preclinical Data Showcase: VY1706 demonstrates compelling pharmacology and safety in a three-month GLP toxicology study in non-human primates, indicating its potential as a treatment for Alzheimer's disease, with clinical trials expected to commence in the second half of 2026, potentially offering new therapeutic options for patients.
- Technological Innovation: The novel AAV capsids developed through Voyager's TRACER platform effectively penetrate the blood-brain barrier and achieve widespread drug expression, enhancing treatment capabilities for Alzheimer's while opening new avenues for other neurological disorders.
- Immune Evasion Strategy: The application of new technologies allows VY1706 to expand the eligible patient population while minimizing immune responses, which not only improves treatment efficacy but also potentially reduces side effects, increasing patient acceptance.
- Future Development Plans: Voyager aims to submit an IND application in Q2 2026, marking a significant advancement in its Alzheimer's program, which is expected to create new market opportunities and bolster investor confidence.
See More
Voyager Therapeutics CFO Resignation and New Appointment
- Executive Changes: Voyager Therapeutics CFO Nathan Jorgensen announced his resignation effective May 8, 2026, to pursue a new opportunity, leading to potential instability in financial leadership that may affect investor confidence.
- New Financial Leadership: The Board has appointed current COO and CBO Robin Swartz as the new Principal Financial Officer and Treasurer effective immediately, ensuring continuity in financial leadership aimed at stabilizing company operations.
- Enhanced Accounting Oversight: Amy Quinlan has been named Principal Accounting Officer, strengthening the company's accounting oversight, indicating a commitment to financial transparency and compliance.
- Stock Price Reaction: Following the executive changes announcement, Voyager Therapeutics' stock closed approximately 2.60% lower at around $4.12, reflecting market caution regarding the leadership transition.
See More
Voyager Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Voyager Therapeutics reported a Q4 GAAP EPS of -$0.46, beating expectations by $0.07, indicating an improving trend in the company's profitability metrics.
- Collaboration Revenue Surge: The company achieved collaboration revenue of $15.34 million, representing a 144.3% year-over-year increase, which not only exceeded market expectations by $4.85 million but also reflects the success of its strategic partnerships and strong market demand.
- Cash Position: As of December 31, 2025, Voyager's cash, cash equivalents, and marketable securities totaled $201.7 million, ensuring sufficient funding for future R&D and operational activities.
- Market Outlook: With significant growth in collaboration revenue and a robust cash position, Voyager Therapeutics is poised to enhance its competitive edge in the biopharmaceutical sector, supporting the realization of its long-term strategic objectives.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
